IP Library Granted Patent US 10,945,978
Granted Patent B2
US 10,945,978 · App. 16/725,493 · Granted Mar 16, 2021

Treatment and diagnosis of melanoma

Inventors: Sohail F. Tavazoie (New York, NY); Nora Pencheva (New York, NY)
Assignee: The Rockefeller University
A61K31/195A61K31/136A61K31/18A61K31/265A61K31/415A61K31/416A61K31/4155A61K31/4164A61K31/4174A61K31/47A61K31/5377A61K31/675A61K38/177A61K38/1709A61K45/06C07C217/54C07D233/64C07F9/6506C12Q1/6886G01N33/5743C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/178G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,945,978
App. No.
16/725,493
Granted
Mar 16, 2021
Kind
B2
Abstract

The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

Claims (9)

1. A method of treating non-small cell lung cancer in a subject in need thereof, the method comprising administering to the subject compound 25, or a pharmaceutically acceptable salt thereof, one of cisplatin and carboplatin, pemetrexed, and a PD- 1 inhibitor in amounts which together are effective, wherein compound 25 is represented as follows

2. The method of claim 1 , wherein the non-small cell lung cancer is resistant to a kinase inhibitor, a PD- 1 inhibitor, and/or a PD-L 1 inhibitor.

3. The method of claim 1 , wherein the non-small cell lung cancer progressed on or after treatment with a kinase inhibitor, a PD- 1 inhibitor, and/or a PD-L 1 inhibitor.

4. The method of claim 1 , wherein the non-small cell lung cancer has been determined to be, or is predicted to be, resistant to a kinase inhibitor, a PD- 1 inhibitor, and/or a PD-L 1 inhibitor.

5. The method of claim 1 , wherein the non-small cell lung cancer is metastatic.

6. The method of claim 1 , wherein the non-small cell lung cancer has been diagnosed as metastatic.

7. The method of claim 1 , wherein the effective amount is an amount effective to suppress metastatic progression of the non-small cell lung cancer.

8. The method of claim 1 , wherein the one of cisplatin and carboplatin is cisplatin.

9. The method of claim 1 , wherein the one of cisplatin and carboplatin is carboplatin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2025
From: TAVAZOIE, SOHAIL; PENCHEVA, NORA
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 072221/0929 →
Continuity (8)
Continuation 15881231 · Jan 26, 2018
Continuation 15650480 · Jul 14, 2017
Continuation 15228643 · Aug 4, 2016
Continuation 14486477 · Sep 15, 2014
Continuation PCTUS2013054690 · Aug 13, 2013
Provisional Application 61784057 · Mar 14, 2013
Provisional Application 61682339 · Aug 13, 2012
Related Publication 20200230090A1 · Jul 23, 2020
Cited By (1)
US 12,258,303